 | Rs 150 per dose is not sustainable in long run: Bharat Biotech on Centre's Covaxin priceThe company said, as directed by the Government of India, less than 10 per cent of the total production of Covaxin to date has been supplied to private hospitals. |
| Recruitment for clinical trial of Covaxin in 6-12 age group to start at AIIMS from June 15The trial is to be conducted in three parts -- 175 volunteers each in the groups aged 12-18, 6-12 and 2-6 years. |
 | Short supply: Covaxin first shot stops in UttarakhandIt has been learnt that the state has not received adequate supply from the manufacturers. |
 | Covaxin supply issues in Delhi addressed: HCThe court disposed of the three pleas filed by persons who were finding it difficult to get the second dose of Covaxin after getting the first jab as they have been fully vaccinated now. |
| Covaxin's emergency nod push in US failsNo vaccine manufactured or developed from India has ever received emergency use authorisation or full licensure from USFDA. |
| US FDA rejects emergency authorisation for Covaxin, 'recommends' to take full approval routeOcugen is in discussions with the FDA to understand the additional information required to support a BLA submission. |
 | TN receives 85k doses of CovaxinHealth Secy says State needs at least 2 crore doses a month to speed up vaccination drive |
| Final phase 3 trials data on Covaxin in July, says Bharat Biotech; experts question delay"It is unusual to have such a delay, particularly when the second analysis was so close to the sample size of 130 symptomatic cases," said a top virologist who did not wish to be named. |
 | Covaxin stock for 45-plus age group almost over: AtishiOut of Delhi's total 5.50 lakh vaccine stock on Tuesday available for people above 45 years, 5.44 lakh were Covishield and 8,000 Covaxin, the MLA from Kalkaji said. |
 | Punjab to administer Covishield 2nd dose after 28 days to those travelling abroad: MinisterThe Union Ministry of Health and Family Welfare has issued recommendations to provide vaccines to such people who have completed 28 days of their first dose, said Sidhu. |
 | Government sets maximum price of vaccines for private hospitals: Covishield Rs 780 a dose, Covaxin Rs 1410In a letter to all states and union territories on Tuesday, the Health Ministry suggested that appropriate strict action be taken against private vaccination centres for overcharging. |
| Covaxin less effective against B.1.617.2 variant responsible for second wave: StudyResearchers associated with ICMR-National Institute of Virology and Bharat Biotech studied neutralization of the parental B.1 virus and variants of concern- B.1.351 and B.1.617. |
 | Another 44 crore Covid vaccines ordered, 2.16 billion doses by December-end is the promiseWith the latest purchase orders, the government has secured 74 crore coronavirus vaccine doses for the country from August onwards, announced V K Paul. |
 | Ocugen pays USD 15 million upfront to Bharat Biotech for Covaxin rights in CanadaOcugen in a regulatory filing said it has agreed to pay another USD 10 million to Bharat Biotech within a month from the commercial launch of Covaxin in the North American country. |
| Fresh Covaxin only for second dose for 18-44 age group in DelhiIssuing the daily vaccination bulletin on Monday, AAP MLA Atishi said for the 18-44 segment, Delhi has a stock of 40,840 vaccines, out of which 40,300 are Covaxin doses. |
